UVA scientists create AI tool for disease treatment development

Scientists at the University of Virginia School of Medicine have developed a new AI tool that aims to speed up the process of finding treatments for diseases. The tool, named LogiRx, goes further than typical AI methods. It not only identifies which patients might benefit from certain drugs but also explains how these drugs act inside cells. The researchers have already shown the tool’s capabilities by finding a new use for the antidepressant escitalopram, known as Lexapro. This drug may help prevent heart failure, a serious health issue that leads to many deaths worldwide. LogiRx can predict how drugs influence biological processes, helping scientists understand both their intended effects and unexpected benefits. Heart failure results in over 400,000 deaths each year in the U.S. One key issue is cardiac hypertrophy, where the heart muscle thickens and affects blood pumping. The team, led by PhD student Taylor Eggertsen, tested LogiRx on 62 drugs previously considered for treating heart issues. The tool identified seven drugs that might prevent harmful cell growth, and lab tests confirmed two of these findings. To further validate LogiRx's predictions, the researchers compared results from lab tests to data from patients taking these medications. They found that patients on escitalopram were less likely to experience cardiac hypertrophy. Eggertsen highlighted that LogiRx could reveal new uses for existing drugs that are already safe for patients. More research and clinical trials will be necessary before doctor's can prescribe escitalopram for heart conditions. However, there is optimism that LogiRx could help develop treatments for various serious illnesses. The findings have been published in a scientific journal, and the research team members reported no financial interests related to their work.